Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate.

Alcohol, clinical & experimental research - 1 Jun 2025

Kranzler Henry R, Jinwala Zeal, Davis Christal N, Xu Heng, Biernacka Joanna M, Zhou Hang, Kember Rachel L, Gelernter Joel, Feinn Richard

Abstract excerpt

BACKGROUND: In two 12-week, randomized, placebo-controlled trials (RCTs) in individuals with alcohol use disorder (AUD), topiramate significantly reduced heavy drinking days (HDDs), and alcohol-related problems. In a secondary analysis of those findings, we examined four broad measures of genetic risk-polygenic scores (PGS)-of problematic alcohol use (PAU), drinks per week (DPW), and time to relapse to any...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Fructose

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TRH gene

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Multifactorial Inheritance

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40445294
DOI: 10.1111/acer.70052
PMCID: PMC12173784

Genes

TRH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Moderation of treatment outcomes by polygenic risk for alcohol-related traits in placebo-controlled trials of topiramate.PMID 40445294Read ↗

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Semantic proximity Read ↗

Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.Semantic proximity Read ↗

Posttreatment effects of topiramate treatment for heavy drinking.Semantic proximity Read ↗

An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Semantic proximity Read ↗

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.Semantic proximity Read ↗

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics studySemantic proximity Read ↗

Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics StudySemantic proximity Read ↗

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.Semantic proximity Read ↗

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Semantic proximity Read ↗

High Polygenic Risk Scores Are Associated With Early Age of Onset of Alcohol Use Disorder in Adolescents and Young Adults at RiskSemantic proximity Read ↗

Predicting treatment-seeking status for alcohol use disorder using polygenic scores and machine learning in a deeply-phenotyped sample.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.